Starmer's government finalizes US drug deal risking £44.7 billion NHS cost
Keir Starmer's government finalized a controversial US pharmaceutical deal in December that could cost the NHS up to £44.7 billion by 2030. Analysis published in the British Medical Journal reveals voters were misled, contradicting promises that the NHS would not be impacted. Critics argue the agreement undermines Britain's healthcare system and lacks adequate parliamentary scrutiny.
How does this story land?
Summary by OZbrief Editorial · The Guardian Australia · Source
Take it further — get the full app and never miss a moment of what's happening in Australia.
This publisher's site can't be shown here due to their security settings.
Open full article →No source link available for this article.
Published 02 Jul 2026, 05:00 UTC · Updated 02 Jul 2026, 05:50 UTC
Summary by OZbrief Editorial. Original report: The Guardian Australia. Editorial policy · Corrections
Trending
- 'It's who we are': Albanese issues impassioned defence of multiculturalism
- Adam Liaw’s brown sugar pudding
- 2026 Midwinter Ball: Political statements make an entrance
- ‘Witch-hunt’ in Niger as military regime rounds up LGBTQ+ population
- Aussie musicians vow to make voices heard in AI copyright war
- Football-free zone: Wimbledon extends World Cup screening ban to players’ lounge